Have a feature idea you'd love to see implemented?
Let us know!
REPL Replimune Group Inc
Price (delayed)
$11.05
Market cap
$756.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.05
Enterprise value
$716.94M
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary
Highlights
The company's EPS rose by 7% QoQ
The net income has contracted by 7% YoY but it has grown by 3.2% from the previous quarter
Replimune Group's debt has increased by 25% YoY
Replimune Group's quick ratio has decreased by 25% from the previous quarter and by 21% YoY
Key stats
What are the main financial stats of REPL
Market
Valuations
Earnings
Shares outstanding
68.42M
Market cap
$756.01M
Enterprise value
$716.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$205.18M
EBITDA
-$202.14M
Free cash flow
-$188.31M
Per share
Balance sheet
Liquidity
EPS
-$3.05
Free cash flow per share
-$2.4
Book value per share
$5.58
Revenue per share
$0
TBVPS
$6.34
Total assets
$498.2M
Total liabilities
$116.74M
Debt
$76.12M
Equity
$381.46M
Working capital
$398.85M
Debt to equity
0.2
Current ratio
10.11
Quick ratio
9.97
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41.5%
Return on equity
-53.1%
Return on invested capital
-46.8%
Return on capital employed
-45.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
REPL stock price
How has the Replimune Group stock price performed over time
Intraday
-1.6%
1 week
-3.07%
1 month
-2.64%
1 year
5.94%
YTD
31.08%
QTD
0.82%
Financial performance
How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$231.58M
Net income
-$213.02M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 8% year-on-year but it has increased by 2.1% since the previous quarter
The net income has contracted by 7% YoY but it has grown by 3.2% from the previous quarter
Growth
What is Replimune Group's growth rate over time
Valuation
What is Replimune Group stock price valuation
P/E
N/A
P/B
1.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 7% QoQ
REPL's price to book (P/B) is 41% higher than its last 4 quarters average of 1.4 but 18% lower than its 5-year quarterly average of 2.4
The company's equity fell by 18% YoY and by 11% QoQ
Efficiency
How efficient is Replimune Group business performance
REPL's ROE is down by 42% YoY
Replimune Group's return on assets has decreased by 30% YoY
Replimune Group's return on invested capital has decreased by 25% YoY
Dividends
What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for REPL.
Financial health
How did Replimune Group financials performed over time
REPL's current ratio is down by 25% QoQ and by 21% YoY
Replimune Group's quick ratio has decreased by 25% from the previous quarter and by 21% YoY
Replimune Group's debt is 80% less than its equity
The debt to equity has surged by 54% year-on-year and by 11% since the previous quarter
Replimune Group's debt has increased by 25% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.